Introduction {#sec1}
============

Recurrent bloodstream infections are either reinfections or relapses caused by the same strain. Bloodstream recurrent infections have been reported for a great variety of opportunistic bacteria, with coagulase-negative staphylococci being the most common [@bib1]. The majority of the relapsing sepsis infections are either catheter related or are caused by indwelling devices that serve as an excellent solid phase for sticky biofilms, the source for transient bacterial translocation into the vessel lumen. Relapsing *Escherichia coli* bacteraemias have also been described [@bib2], [@bib3], [@bib4], [@bib5]. Molecular fingerprinting [@bib2], [@bib3] as well as biochemical analysis and serotyping [@bib4] have shown that the majority of the sepsis episodes might be caused by the same strain even when adequate antimicrobial therapy is provided. Taking into account the multistrain and multispecies complexity of biofilm, it remains unclear why sepsis episodes are often caused by exactly the same strain and what kind of "leads" this strain may have compared to other "inhabitants" of the biofilm ecosystem.

Here we report a case of recurrent *E. coli* sepsis. Altogether, the patient experienced seven episodes of *E. coli* bacteraemia in just over a year. All the episodes can be considered as relapses caused by the extended-spectrum β-lactamase (ESBL) strain or by the AmpC hyperproducer. Finally, the focus of these bloodborne infections was found in his spleen and pancreas cauda, which was resected. Of interest, the underlying disease, autoimmune pancreatitis of type 1 with IgG4 hyperglobulinaemia, had probably contributed to the formation of the cyst that harboured infection.

Case Report {#sec2}
===========

A 47-year-old man came to Finland as a refugee from Southeast Asia. In the immigration health inspection, he was diagnosed with a *Toxocara canis* infection and treated with mebendazole. Soon after arrival, he complained of epigastric pain and fever; he was diagnosed with acute pancreatitis, which was treated conservatively. After this episode, the patient gave up alcohol completely. Pancreatitis episodes, often complicated with septicaemias, recurred several times during the following years. Radiologic findings confirmed chronic pancreatitis with calcifications. Papillotomy, dilatation and stent insertion into the strictured ductus Wirsung were performed. Written informed consent was obtained from the patient.

Three years after the first pancreatic episode, the patient was hospitalized again for fever and multiple liver abscesses. Abscesses were also found in the spleen and pancreas. Blood cultures revealed *Lactococcus* species. Drainage of abscesses was not feasible because of the small size of the multiple abscesses and the challenging anatomic site. An infection of the pancreatic duct stent was suspected, and the stent was removed. ESBL-producing *Escherichia coli* septicaemia complicated the surgical intervention. The condition progressed despite long-term antimicrobial therapy.

The patient was negative for parasitic infection, HIV, and *Echinococcus* serology. Instead, *Toxocara canis* serology remained positive, compatible with his early infection. During the following months, the patient was hospitalized several times for recurrent pancreatitis and relapsing episodes of sepsis. The laboratory data on the blood culture isolates are presented in [Table 1](#tbl1){ref-type="table"}.

Abscess formation continued even though the patient received various antimicrobials ([Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}). Eventually cholecystectomy, splenectomy and a partial pancreatic resection were considered. In addition to resection of the pancreatic cauda, the enlarged spleen was removed, and cholecystectomy was performed. Histopathologic examination of the pancreas revealed extensive fibrosis, multiple cysts (1--2 cm in diameter) and inflammatory cells such as neutrophils, macrophages, lymphocytes and plasma cells that were partly immunopositive for IgG4. Histology revealed no microorganisms. The hilum of the spleen revealed purulent inflammation, but the splenic parenchyma and gallbladder were structurally normal. Computed tomographic scan revealed numerous degenerative cystic lesions in the spleen that most probably had formed as a result of prolonged bacterial infection ([Fig. 1](#fig1){ref-type="fig"}). A pseudocyst filled with a grey fluid was found between the pancreatic cauda and the spleen. ESBL *E. coli* was isolated from the fluid. All other tissue cultures were negative in bacteriologic, mycobacteriologic, virologic and parasitologic examinations. These findings finally confirmed suspected end-stage chronic autoimmune pancreatitis associated with the IgG4 syndrome [@bib6]. During convalescence, the patient had a relapse of ESBL *E. coli* sepsis but recovered completely.

The strains were tested for β-lactamase genes as previously described [@bib7]. All 3 ESBL isolates harboured a *CTX-M* gene. Three other *E. coli* isolates ([Table 1](#tbl1){ref-type="table"}) had an AmpC phenotype and were negative for *ampC* genes (*CIT, DHA, MOX, FOX, EBC, ACC*), thus apparently overproducing the chromosomal AmpC. In order to investigate the clonality of the strains, we performed molecular typing. The culture isolates were analysed with pulsed-field gel electrophoresis using a protocol based on PulseNet for *E. coli* (<http://www.cdc.gov/pulsenet/pathogens/ecoli.html>). Briefly, genomic DNA was digested with *Xba*I (New England Biolabs), and separated in a Chef DR III (Bio-Rad). Banding patterns were interpreted using the criteria of Tenover *et al*. [@bib8]. The ESBL isolates were found to be the same strain (one- to two-band differences in the banding patterns). The AmpC overproducers were also similar (a one-band difference in one isolate); however, they were different from the ESBL clone ([Fig. 2](#fig2){ref-type="fig"}).

Soon after the surgical intervention, our patient experienced a new episode of ESBL sepsis---a complication that might have been avoided if previous bacteriologic data had been taken into account so perioperative carbapenem prophylaxis could have been implemented.

Discussion {#sec3}
==========

The reported case emphasizes that the primary prevention of bloodstream relapses caused by Gram-negative bacteria is the surgical elimination of the focus of infection. Being encapsulated in a cyst, the bacteria are well protected against the bactericidal action of antimicrobials even in organs with good vascularization such as the pancreas.

Relapses of bacteraemia with enterobacteria can occur in patients with underlying gastrointestinal or autoimmune disorders, as in our case. These episodes can be caused by resistant bacteria, which should be considered during perioperative protection after the first sepsis episode. Surgical removal of the focus of infection could be curative.
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![Radiologic description of computed tomographic scan of the body (shortened). Liver is diffusely fatty without clear features of cirrhosis. Spleen is enlarged, with craniocaudal dimension of 14 cm. In hilus region there are small fingerlike liquid retentions that could be traits of abscesses or pseudocysts. Prominent lymphatic node is evident between ventricle and spleen, with dimension of 11 mm. Corpus and cauda of pancreas are atrophic; ducts are widened, maximum 7--8 mm at corpus region. Abundance of calcified lesions in caput is compatible with chronic pancreatitis. Region of abscesses in spleen is circled. Breathing artifact is evident in abdominal region.](gr1){#fig1}

![Pulsed-field gel electrophoresis of strains. Lanes 1, 5 and 10, control strain; lanes 2--4, 2 AmpC overproducer; lanes 6--9, ESBL strain. ESBL, extended-spectrum β-lactamase.](gr2){#fig2}

###### 

Characteristics of isolated *Escherichia coli* strains from blood culture samples and pancreatic cyst

  Sepsis episode   Organism         Antimicrobial susceptibility (mm) (interpretation)                                                                                    
  ---------------- ---------------- ---------------------------------------------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- --------
  April 2013       ESBL *E. coli*   22 (I)                                               6 (R)    20 (S)   6 (R)    30 (S)   30 (S)   20 (S)   21 (I)   ND       ND       ND
  May 2013         ESBL *E. coli*   22 (I)                                               6 (R)    20 (S)   6 (R)    30 (S)   30 (S)   20 (S)   21 (I)   ND       ND       ND
  August 2013      AmpC *E. coli*   24 (S)                                               35 (S)   22 (S)   27 (S)   28 (S)   29 (S)   ND       23 (I)   27 (S)   18 (S)   21 (I)
  November 2013    AmpC *E. coli*   24 (S)                                               35 (S)   22 (S)   27 (S)   28 (S)   29 (S)   ND       23 (I)   27 (S)   18 (S)   21 (I)
  March 2014       AmpC *E. coli*   24 (S)                                               35 (S)   22 (S)   27 (S)   28 (S)   29 (S)   ND       23 (I)   27 (S)   18 (S)   21 (I)
  March 2014       ESBL *E. coli*   25 (I)                                               6 (R)    20 (S)   6 (R)    27 (S)   30 (S)   ND       18 (R)   ND       ND       ND
  May 2014         ESBL *E. coli*   25 (I)                                               6 (R)    20 (S)   6 (R)    27 (S)   30 (S)   ND       18 (R)   ND       ND       ND

CAZ, ceftazidime; CIP, ciprofloxacin; CRO, ceftriaxone; CXM, cefuroxime; ESBL, extended-spectrum β-lactamase; ETP, ertapenem; I, intermediate; MEM, meropenem; ND, not determined; NET, netilmicin; R, resistant; S, susceptible; TOB, tobramycin; TZP, piperacillin--tazobactam.

###### 

Antibiotic treatment of patient in periods between bacteraemia episodes

  Date            Duration of administration (days)                      
  --------------- ----------------------------------- --- ---- ---- ---- ---
  April 2013                                                             7
                  3                                                      
                                                               14   14   
  March 2013                                              9              
  May 2013                                                     19   19   
                                                          18             
  August 2013                                                            2
                                                          14             
                                                      4                  
  December 2013   4                                                      
                                                          13             
  February 2014                                           13             
  March 2014                                              3              
                  7                                                      
                                                      7                  
  April 2014                                          5                  
                                                                    14   
  May 2014        2                                                      
                                                          14   14        

CIP, ciprofloxacin; CXM, cefuroxime; ETP, ertapenem; MEM, meropenem; TZP, piperacillin--tazobactam; VAN, vancomycin.

###### 

Drug dosages and routes

  Drug abbreviation   Drug name                  Dosages (per day)   Administration route
  ------------------- -------------------------- ------------------- ----------------------
  CXM                 Cefuroxime                 1.5 g × 3           iv
  TZP                 Piperacillin--tazobactam   4 g × 3             iv
  MEM                 Meropenem                  1 g × 3             iv
  ETP                 Ertapenem                  1 g × 1             iv, po
  VAN                 Vancomycin                 1 g × 2             iv
  CIP                 Ciprofloxacin              500 mg × 2          po

iv, intravenous; po, by mouth.
